Voyager Acquisition Approves Veraxa Merger with 99.67% Redemption, $885,556 Remaining
Voyager Acquisition Corporation shareholders approved a business combination with Veraxa Biotech AG, redeeming 25,217,315 Class A shares—99.67% of total outstanding—leaving $885,556 in its trust account. If no redemption withdrawals occur, 82,685 Class A shares convert into shares of combined Veraxa Biotech Holding AG, listing on Nasdaq under ticker VRXA pending approvals.
1. Merger Approval
On March 12, 2026, Voyager Acquisition Corporation held its general meeting and secured shareholder approval for the previously announced business combination with Veraxa Biotech AG, setting the stage for a new publicly traded entity.
2. Redemption Statistics
A total of 25,217,315 Class A ordinary shares were submitted for redemption—representing approximately 99.67% of all outstanding Class A shares—with $885,556 remaining in the trust account after these redemptions.
3. Post-Combination Listing
Assuming no redemption withdrawals, 82,685 Class A shares will convert into shares of the combined Veraxa Biotech Holding AG, which is expected to list on the Nasdaq under the symbol VRXA upon receipt of required listing approvals and satisfaction of closing conditions.